ProPhase Labs Total Long Term Liabilities 2010-2025 | PRPH

ProPhase Labs total long term liabilities from 2010 to 2025. Total long term liabilities can be defined as the sum of all non-current liabilities.

ProPhase Labs Total Long Term Liabilities 2010-2025 | PRPH

ProPhase Labs total long term liabilities from 2010 to 2025. Total long term liabilities can be defined as the sum of all non-current liabilities.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$69.6B
Zoetis (ZTS)$69B
Takeda Pharmaceutical (TAK)$48.7B
Daiichi Sankyo, - (DSNKY)$47.9B
BeOne Medicines - (ONC)$34.4B
Sandoz Group AG (SDZNY)$26.7B
Summit Therapeutics (SMMT)$19.3B
Merck (MKKGY)$16.7B
Shionogi (SGIOY)$14.9B
United Therapeutics (UTHR)$14B
Neurocrine Biosciences (NBIX)$13.4B
IPSEN (IPSEY)$11.3B
Orion OYJ (ORINY)$11.2B
Eisai (ESAIY)$9.1B
Madrigal Pharmaceuticals (MDGL)$9B
Corcept Therapeutics (CORT)$7.5B
Grifols, S.A (GRFS)$6.9B
Stevanato Group S.p.A (STVN)$6.9B
Ionis Pharmaceuticals (IONS)$6.9B
Ono Pharmaceutical (OPHLF)$5.7B
Hikma Pharmaceuticals Plc (HKMPF)$5.4B
Soleno Therapeutics (SLNO)$3.7B
Procaps Group, S.A (PROCF)$3.2B
AMNEAL PHARMACEUTICALS, INC (AMRX)$3B
Crinetics Pharmaceuticals (CRNX)$2.8B
NewAmsterdam Pharma (NAMS)$2.8B
Hypermarcas (HYPMY)$2.7B
Catalyst Pharmaceuticals (CPRX)$2.5B
Centessa Pharmaceuticals (CNTA)$2.3B
Ocular Therapeutix (OCUL)$2.1B